Aurion Biotech

Aurion Biotech has made meaningful progress in the regenerative cell therapy space with the commercialization of Vyznova® in Japan, a cell therapy developed to treat bullous keratopathy, a serious corneal condition that can cause pain and vision impairment.     Vyznova® is the first approved regenerative cell therapy for corneal endothelial disease in Japan, with both regulatory and reimbursement approval, marking an important milestone in expanding access to innovative vision-restoring care.     This progress, alongside U.S. FDA Breakthrough Therapy Designation and Regenerative Medicine Advanced Therapy designation for Aurion’s investigational programs, reflects the company’s commitment to advancing regenerative therapies globally.     Learn more about our science and pipeline here: https://lnkd.in/gp-i-b97    #AurionBiotech #RegenerativeCellTherapy #Ophthalmology #GlobalHealth #VisionRestoration #Hope #BTD #RMAT 

Thank you to BiotechTV for featuring Aurion Biotech's CEO, Arnaud Lacoste, PhD MBA, following his presentation at #ASGCT2026. Arnaud presented on "Designing a Large-Scale Cell Therapy: Clinical Validation and Early Commercialization of Corneal Endothelial Cell Therapy," sharing Aurion's progress in advancing regenerative cell therapy for patients with corneal endothelial disease, where access to donor tissue for traditional cornea transplantation remains a significant challenge.   We're grateful for the opportunity to share our story and the science behind our work - be sure to check out the Biotech TV interview below.    #AurionBiotech #RegenerativeCellTherapy #Ophthalmology #Hope

Join Aurion Biotech at #ASGCT2026 for an upcoming oral presentation on regenerative cell therapy for corneal endothelial disease. Aurion Biotech is dedicated to developing transformative regenerative cell therapies designed to restore vision for patients with corneal endothelial disease, where access to donor tissue for a one-to-one cornea transplantation continues to be a challenge. ▪️Title: Designing a Large-Scale Cell Therapy: Clinical Validation and Early Commercialization of Corneal Endothelial Cell Therapy  ▪️Presenter: Arnaud Lacoste, PhD MBA, CEO and CSO, Aurion Biotech  ▪️Date/Time: May 15, 2026 | 8:30 – 8:45 AM ET  ▪️Session: Long-term safety and durable efficacy in cell and gene therapy  ▪️Location: Meeting Room 257AB We invite you to attend and learn more about Aurion Biotech’s approach to advancing scalable regenerative cell therapy. #AurionBiotech #ASGCT #GeneTherapy #RegenerativeCellTherapy #Ophthalmology #Hope

Aurion Biotech is looking forward to presenting at #ASGCT2026 next week. We are excited to connect with colleagues, share insights, and continue learning alongside leaders advancing the future of cell and gene therapy. We are also proud to share that our CEO and Chief Scientific Officer, Arnaud Lacoste, PhD MBA, will be presenting new insights on regenerative cell therapy for corneal endothelial disease: ▪️Presentation Title: Designing a Large-Scale Cell Therapy: Clinical Validation and Early Commercialization of Corneal Endothelial Cell Therapy  ▪️Date/Time: May 15, 2026 | 8:30 – 8:45 AM ET  ▪️Session: Long-term safety and durable efficacy in cell and gene therapy  ▪️Location: Meeting Room 257AB We look forward to being part of the important conversations shaping the future of regenerative cell therapy.  Read the full announcement here: https://lnkd.in/gDiWPVbz #AurionBiotech #ASGCT #RegenerativeCellTherapy #GlobalInnovation #Ophthalmology #Hope 

Thank you to Conner Harman for having Sterling Chung, our Chief Regulatory & Quality Officer, on for an episode of the Regulatory Voices podcast. We're so pleased to have members of our leadership team participating in meaningful conversations surrounding regulatory decision making. #AurionBiotech #RegenerativeCellTherapy #Regulatory #RegulatoryVoicesPodcast #Hope

In October 2025, Aurion Biotech shared positive 12-month results from the Phase 1/2 CLARA trial evaluating AURN001 in patients with corneal endothelial disease.    A clear dose-dependent response and the greatest efficacy was observed in the high-dose combination group. Patients in this group experienced meaningful improvements in best corrected visual acuity, corneal thickness, and patient-reported quality-of-life measures.    The CLARA trial results continue to serve as an important foundation for Aurion Biotech’s continued clinical development of the Corneal Endothelial Cell Therapy (CECT).   Learn more about the CLARA trial here: https://lnkd.in/eR_36dUe Caution: AURN001 is investigational and not approved by the FDA   #AurionBiotech #ClinicalTrials #RegenerativeCellTherapy #Ophthalmology #VisionScience #Hope 

If you are attending ASCRS, we invite you to attend Brandon Ayres, MD, American Board of Ophthalmology’s presentation titled “Results of the Prospective, Double-Masked Clara Study of Human Corneal Endothelial Cell Therapy for Corneal Endothelial Dysfunction.”     Dr. Ayres will be presenting on Monday, April 13th at 8:20 AM during the "Cornea Procedures & Outcomes - Other" Session, sharing insights on clinical outcomes from the CLARA study evaluating human corneal endothelial cell therapy for corneal endothelial dysfunction.     We look forward to engaging with the community around this important discussion.     Learn more about Aurion Biotech’s clinical and scientific work here: https://aurionbiotech.com/   #AurionBiotech #ScientificExchange #Ophthalmology #ClinicalResearch #RegenerativeCellTherapy #MedicalEducation #Hope #ASCRS2026 

Aurion Biotech’s Chief Medical Officer, Edward J. Holland, M.D., is featured in Healio | Ocular Surgery News as part of the latest CEDARS/ASPENS Debates, exploring the future of Corneal Endothelial Cell Therapy (CECT). In the article, Dr. Holland shares how this innovative, cell-based approach builds on decades of pioneering research from Dr. Shigeru Kinoshita to offer a minimally invasive alternative to traditional transplant procedures. By using cultured human endothelial cells delivered through a single injection, this therapy has the potential to expand access, reduce surgical burden, and improve outcomes for patients worldwide. With more than 275 eyes treated across clinical studies and no observed rejections, even 10 years after treatment, the data continues to reinforce both the safety and durability of this approach.  Read Dr. Holland’s perspective on the science, clinical outcomes, and what lies ahead for CECT in Healio’s article here: https://lnkd.in/grtG9GNr   #AurionBiotech #RegenerativeCellTherapy #BiotechInnovation #HealioOSN #Healio #Hope 

Pivotal Milestone Achieved: Aurion Biotech has reached an important milestone in advancing regenerative cell therapy for corneal endothelial disease. We are proud to announce that the first patients have been dosed in the U.S. ASTRA Phase 3 pivotal study evaluating AURN001, our investigational, single-administration therapy designed to restore corneal clarity and vision.    This study represents a critical step toward potentially delivering the first cell therapy in the U.S. for patients with corneal edema secondary to corneal endothelial dysfunction. By moving beyond traditional donor tissue-based surgery, AURN001 aims to expand access to care and improve the patient experience. We are grateful to the investigators, clinical sites, and patients who are making this progress possible, and we remain committed to our mission to restore vision through regenerative cell therapy. Read the full announcement here: https://lnkd.in/g6FJWy8i #AurionBiotech #Ophthalmology #ClinicalResearch #RegenerativeCellTherapy #PivotalMilestone #Hope  

Aurion Biotech is looking forward to attending #ASCRS2026, taking place April 10–13 in Washington, DC.    We are especially proud to sponsor Cornea Day, a premier program bringing together leaders in corneal disease and surgery to share the latest advances shaping the field.    We are also excited to see Marjan Farid, M.D., Chair of Aurion Biotech’s Medical Advisory Board, serving as a Program Chair for Cornea Day. Her leadership and dedication to advancing corneal care reflect the collaborative spirit that drives progress in ophthalmology.    Members of the Aurion Biotech team will be onsite and look forward to connecting with clinicians, researchers, and industry colleagues to share more about our work advancing AURN001 and our mission to restore vision through regenerative cell therapy.    If you would like to schedule time with the team, contact us here: https://lnkd.in/ecMxtyzm   We look forward to connecting in Washington, DC.    #AurionBiotech #ASCRS2026 #Ophthalmology #Cornea #RegenerativeCellTherapy #VisionScience